Available Treatment Options for Patients With R/R MM
Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.
EP: 1.The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma
EP: 2.Triplet and Quadruplet Induction Regimen Options for Patients With Transplant-Eligible NDMM
EP: 3.Data Updates From GRIFFIN and MASTER in Transplant-Eligible NDMM
EP: 4.Exploring the GMMG-CONCEPT Study in Patients With Transplant-Eligible NDMM
EP: 5.Assessing and Treating Patients with High-Risk NDMM
EP: 6.Treatment Approaches in Patients With Transplant-Ineligible NDMM
EP: 7.Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population
Now Viewing
EP: 8.Available Treatment Options for Patients With R/R MM
EP: 9.Updated Results of the MonumenTAL-1 Study in R/R MM
EP: 10.Application of Bispecific Therapy in Clinical Practice
EP: 11.Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma
EP: 12.Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
EP: 13.Unmet Needs in the Treatment of Multiple Myeloma
EP: 14.Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and Satellites
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
